HER2-Mutant NSCLC Update: Expanded Approval of Zongertinib

Click here to view the full CME/NCPD/CPE/AAPA activity and hear additional insights on the HER2-mutant NSCLC treatment landscape! The FDA’s recent expanded approval of zongertinib marks a significant milestone in the treatment of non-small cell lung cancer (NSCLC). As the first oral human epidermal growth factor receptor 2 (HER2) inhibitor to move into the frontline setting, this therapy offers a new standard of care for patients with metastatic or unresectable non-squamous NSCLC harboring HER2 mutations. Following the approval, Beth Sandy, Thoracic Oncology Nurse Practitioner at the University of Pennsylvania, sat down to explore its clinical implications, including efficacy data, side effect management, and the potential of having a once-daily oral pill for improving patient experiences.

You can listen to HER2-Mutant NSCLC Update: Expanded Approval of Zongertinib online on Radio and Podcast. Open the player on this page to stream the available audio.

HER2-Mutant NSCLC Update: Expanded Approval of Zongertinib is an episode from Oncology Data Advisor by Oncology Data Advisor™.

This episode is 00:06:23 long.

This episode was published on Apr 3, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Oncology Data Advisor when more episodes are available from the podcast feed.